News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antisoma PLC (ASM.L) Announces Discontinuation of Development of AS1402


8/7/2009 8:06:49 AM

Bookmark and Share

London, UK, and Cambridge, MA: Antisoma plc today announces that the phase II trial of AS1402 in breast cancer is to be discontinued. This follows a meeting of the trial’s Data Monitoring Committee (DMC) and a subsequent review of the data, which led the company to conclude that the trial would be very unlikely to give sufficiently positive efficacy findings. No safety concerns were identified. Antisoma has no plans for further studies of AS1402.

Read at Company Press Release
Read at Reuters

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES